研究型制药工业与社会:未来的利害关系是什么?

Karl Wündisch
{"title":"研究型制药工业与社会:未来的利害关系是什么?","authors":"Karl Wündisch","doi":"10.3109/J058V16N01_04","DOIUrl":null,"url":null,"abstract":"ABSTRACTThe US House of Representatives passed the far-reaching Pharmaceutical Market Access Act in July of 2003. If this bill or any similar language becomes law, the provision of health care would be affected radically on a worldwide basis. The author discusses the implications of such a law for governments, society, the pharmaceutical industry, and consumers, touching on societal expectations for cures and diagnostic procedures, aims and results of government regulation of the pharmaceutical industry, individual responsibility for health, and the situation of research-based and biotech enterprises as shouldering both social and commercial responsibility for health care. The author also addresses the economic risks of research-based and biotech enterprises, the need for transparency in cost structure, the funding of R&D, marketing costs for new products, the parallel imports market, and the effects of government reimbursement decisions.","PeriodicalId":16734,"journal":{"name":"Journal of Pharmaceutical Marketing & Management","volume":"2 1","pages":"21-40"},"PeriodicalIF":0.0000,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"The Research-Based Pharmaceutical Industry and Society: What Is at Stake in the Future?\",\"authors\":\"Karl Wündisch\",\"doi\":\"10.3109/J058V16N01_04\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"ABSTRACTThe US House of Representatives passed the far-reaching Pharmaceutical Market Access Act in July of 2003. If this bill or any similar language becomes law, the provision of health care would be affected radically on a worldwide basis. The author discusses the implications of such a law for governments, society, the pharmaceutical industry, and consumers, touching on societal expectations for cures and diagnostic procedures, aims and results of government regulation of the pharmaceutical industry, individual responsibility for health, and the situation of research-based and biotech enterprises as shouldering both social and commercial responsibility for health care. The author also addresses the economic risks of research-based and biotech enterprises, the need for transparency in cost structure, the funding of R&D, marketing costs for new products, the parallel imports market, and the effects of government reimbursement decisions.\",\"PeriodicalId\":16734,\"journal\":{\"name\":\"Journal of Pharmaceutical Marketing & Management\",\"volume\":\"2 1\",\"pages\":\"21-40\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2003-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pharmaceutical Marketing & Management\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3109/J058V16N01_04\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Marketing & Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3109/J058V16N01_04","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

摘要美国众议院于2003年7月通过了影响深远的《药品市场准入法案》。如果这项法案或任何类似的措词成为法律,在世界范围内提供保健服务将受到根本影响。作者讨论了这样一项法律对政府、社会、制药行业和消费者的影响,涉及社会对治疗和诊断程序的期望、政府对制药行业监管的目标和结果、个人对健康的责任,以及研究型和生物技术企业承担医疗保健的社会和商业责任的情况。作者还讨论了研究型企业和生物技术企业的经济风险、成本结构透明度的必要性、研发资金、新产品的营销成本、平行进口市场以及政府报销决策的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The Research-Based Pharmaceutical Industry and Society: What Is at Stake in the Future?
ABSTRACTThe US House of Representatives passed the far-reaching Pharmaceutical Market Access Act in July of 2003. If this bill or any similar language becomes law, the provision of health care would be affected radically on a worldwide basis. The author discusses the implications of such a law for governments, society, the pharmaceutical industry, and consumers, touching on societal expectations for cures and diagnostic procedures, aims and results of government regulation of the pharmaceutical industry, individual responsibility for health, and the situation of research-based and biotech enterprises as shouldering both social and commercial responsibility for health care. The author also addresses the economic risks of research-based and biotech enterprises, the need for transparency in cost structure, the funding of R&D, marketing costs for new products, the parallel imports market, and the effects of government reimbursement decisions.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信